Condition: Diabetic Kidney Disease (DKD) · Sponsor: Aptabio Therapeutics, Inc.
This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.
This description comes directly from the study's public registry record.
Sung Jun Lim · +82-31-365-3693 · cd@aptabio.com
Always discuss trial participation with your own doctor first.
| Korea University Ansan Hospital | Ansan-si, South Korea | Recruiting |
| Inje university Busan Paik Hospital | Busan, South Korea | Not Yet Recruiting |
| Pusan National University Hospital | Busan, South Korea | Recruiting |
| SoonChunHyang University Hospital Cheonan | Cheonan, South Korea | Recruiting |
| Keimyung University Daegu Dongsan Hospital | Daegu, South Korea | Recruiting |
| Inje university Ilsan Paik Hospital | Goyang-si, South Korea | Recruiting |
| Hanyang University Guri Hospital | Guri-si, South Korea | Recruiting |
| Chung-Ang University Gwangmyeong Hospital | Gwangmyeong, South Korea | Recruiting |
| The Catholic University of Korea Incheon St. Mary's Hospital | Incheon, South Korea | Recruiting |
| Jeonbuk National University Hospital | Jeonju, South Korea | Not Yet Recruiting |
| CHA Bundang Medical Center | Seongnam-si, South Korea | Recruiting |
| Boramae Medical Center | Seoul, South Korea | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06962098